George J Hanna MD (He/Him)
HIV/AIDS Medicine
Independent Pharmaceutical Consultant with Expertise in Clinical Drug Development, Scientific and Medical Affairs, and Infectious Diseases
Join to View Full Profile
1805 Stuart Rd WPrinceton, NJ 08540
Dr. Hanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- George Hanna, MD, is a clinical drug development and Infectious Disease specialist located in Princeton, NJ. He completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center and his fellowship in Infectious Disease at Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School. Dr. Hanna has held various leadership roles in pharmaceutical companies, including Merck and Bristol-Myers Squibb, and is currently working as an Independent Pharmaceutical Consultant. His published research has focused on antiviral treatment for HIV, viral hepatitis, and COVID-19, with several studies appearing in reputable medical journals. Dr. Hanna has also been involved in clinical development of antiretroviral therapies for HIV as well as antiviral therapies for viral hepatitis and respiratory viruses.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1996 - 2000
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Baylor College of MedicineClass of 1992
Certifications & Licensure
NJ State Medical License 2009 - 2027
PA State Medical License 2001 - 2026
IL State Medical License 2005 - 2008
MA State Medical License 1995 - 2003
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Start of enrollment: 1997 Nov 01
Publications & Presentations
PubMed
- 4 citationsTime to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.Russell L Rothman, Thomas G Stewart, Ahmad Mourad, David R Boulware, Matthew W McCarthy
JAMA Network Open. 2024-10-01 - 18 citationsHigher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, Christopher J Lindsell, David R Boulware
JAMA. 2023-12-26 - 6 citationsThe Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.Nalini Ambrose, Alpesh Amin, Brian Anderson, Monica Bertagnolli, Francis Campion
Journal of General Internal Medicine. 2023-12-01
Press Mentions
Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically SuppressedSeptember 24th, 2019
FDA Approves Expanded Indications for 2 HIV TherapiesSeptember 20th, 2019
Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019July 24th, 2019
Grant Support
- Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases2001
- Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases1999–2001
Professional Memberships
- Member
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/george-hanna-35221924/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
